The company's financial leverage has intensified significantly, with the debt-to-equity ratio rising from 0.34 in 2023Q4 to 1.08 by 2025Q4, reflecting a deteriorating capital structure.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Jul'11 | Jul'10 | Jul'09 |
|---|
| Total Current Assets | 36.89M | 38.39M | 25.46M | 36.61M | 56.04M | 39.83M | 40.77M | 21.18M | 18.35M | 9.51M | 2.64M | 547.18K | 7.21M | 864.92K | 0 | 15.24K | 470 | 0 |
| Cash & Short-Term Investments | 548.93K | 761.83K | 336.25K | 3.85M | 20.76M | 297.95K | 851.19K | 277.48K | 3.58M | 782.85K | 716.59K | 198.05K | 446.6K | 864.49K | 0 | 15.24K | 470 | 0 |
| Cash Only | 514.7K | 715.67K | 315.11K | 3.83M | 20.75M | 286.49K | 628.39K | 38.54K | 864.34K | 782.85K | 716.59K | 198.05K | 446.6K | 864.49K | 0 | 15.24K | 470 | 0 |
| Short-Term Investments | 34.23K | 46.16K | 21.15K | 20.07K | 14.88K | 11.47K | 222.79K | 238.94K | 2.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 21.46M | 22.56M | 15.88M | 21.71M | 22.76M | 30.14M | 26.91M | 9.27M | 4.94M | 1.43M | 793.75K | 96.54K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 107.67 | 126.16 | 106.5 | 148.47 | 165.02 | 195.59 | 177.27 | 85.26 | 48.65 | 17.35 | 42.89 | 66.01 | - | - | - | - | - | - |
| Inventory | 5.65M | 5.78M | 4.36M | 4.79M | 3.45M | 3.15M | 3.29M | 3.47M | 3.2M | 3.09M | 464.22K | 191.87K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 32.57 | 36.76 | 31.72 | 35.65 | 28.38 | 23.98 | 25.38 | 35.21 | 33.71 | 40.24 | 27.53 | 144.46 | - | - | - | - | - | - |
| Other Current Assets | 9.23M | 9.29M | 4.89M | 1.95M | 9.07M | -4.77K | 1.1M | 665.49K | 189.76K | 772.62K | 0 | 0 | 6.73M | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 25.48M | 27.09M | 28.85M | 29.41M | 11.67M | 9.6M | 3.07M | 2.7M | 2.35M | 1.17M | 481.92K | 110.44K | 21.59K | 2.13K | 0 | 0 | 0 | 0 |
| Property, Plant & Equipment | 10.95M | 11.78M | 10.4M | 11.62M | 2.93M | 2.93M | 1.76M | 1.73M | 1.43M | 114.57K | 52.72K | 50.53K | 11.99K | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 5.84x | 5.54x | 5.23x | 4.60x | 17.18x | 19.17x | 31.53x | 22.87x | 26.01x | 261.97x | 128.15x | 10.56x | 636.96x | - | - | - | - | - |
| Goodwill | 49.7K | 49.7K | 49.7K | 49.7K | 49.7K | 49.7K | 49.7K | 49.7K | 49.7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 9.24M | 7.52M | 7.71M | 7.63M | 657.22K | 436.07K | 180.81K | 213.98K | 247.07K | 41.99K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 5.77M | 165.93K | 0 | 0 | 0 | 4.38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5.23M | 7.74M | 4.92M | 9.94M | 8.03M | 5.33M | 905.32K | 698.06K | 624.48K | 1.01M | 429.2K | 59.92K | 9.6K | 2.13K | 0 | 0 | 0 | 0 |
| Total Assets | 62.37M | 65.48M | 54.31M | 66.01M | 68.04M | 49.43M | 43.84M | 23.88M | 20.69M | 10.68M | 3.12M | 657.62K | 7.23M | 867.05K | 0 | 15.24K | 470 | 0 |
| Asset Turnover | 1.07x | 1.00x | 1.00x | 0.81x | 0.74x | 1.14x | 1.26x | 1.66x | 1.79x | 2.81x | 2.17x | 0.81x | 1.06x | 1.04x | - | - | - | - |
| Asset Growth % | 38.98% | 20.56% | -17.73% | -2.97% | 37.65% | 12.74% | 83.61% | 15.39% | 93.85% | 242.33% | 374.21% | -90.91% | 734.39% | - | -100% | 3142.13% | - | - |
| Total Current Liabilities | 34.08M | 38.27M | 25.76M | 24.32M | 21.75M | 29.93M | 34.29M | 28.24M | 22.27M | 13.7M | 4.87M | 1.91M | 1.76M | 920.73K | 1.4K | 20K | 17.95K | 4.6K |
| Accounts Payable | 14.82M | 14.62M | 11.16M | 11.91M | 10.26M | 12.13M | 11.97M | 8M | 5.93M | 2.17M | 591.69K | 336.93K | 159.45K | 530.18K | 1.4K | 0 | 2.08K | 4.6K |
| Days Payables Outstanding | 83.69 | 93.03 | 81.26 | 88.68 | 84.36 | 92.39 | 92.31 | 81.1 | 62.46 | 28.18 | 35.09 | 253.67 | 821.97 | 347.12 | - | - | - | - |
| Short-Term Debt | 11.89M | 13.52M | 9.55M | 8.23M | 8.04M | 13.34M | 19.7M | 18.65M | 15.02M | 10.18M | 3.2M | 474.14K | 504.12K | 165K | 0 | 0 | 15.87K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 22.34K | 247.32K | 1.07M | 0 | 0 | 62.21K | 0 | 671 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.37M | 7.11M | 3.35M | 3.47M | 2.7M | 1.3M | 799.73K | 165.27K | 111.21K | 0 | 0 | 0 | 0 | 186.59K | 0 | -20K | 0 | 0 |
| Current Ratio | 1.08x | 1.00x | 0.99x | 1.51x | 2.58x | 1.33x | 1.19x | 0.75x | 0.82x | 0.69x | 0.54x | 0.29x | 4.10x | 0.94x | - | 0.76x | 0.03x | - |
| Quick Ratio | 0.92x | 0.85x | 0.82x | 1.31x | 2.42x | 1.23x | 1.09x | 0.63x | 0.68x | 0.47x | 0.45x | 0.19x | 4.10x | 0.94x | - | 0.76x | 0.03x | - |
| Cash Conversion Cycle | 56.55 | 69.88 | 56.96 | 95.45 | 109.03 | 127.18 | 110.34 | 39.37 | 19.91 | 29.42 | 35.33 | -43.2 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 8.47M | 8.78M | 4.02M | 5.65M | 6.63M | 15.12M | 13.72M | 2.1M | 1.74M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 6.12M | 5.85M | 1.56M | 3.04M | 2.86M | 12.72M | 11.27M | 0 | 1.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 1.72M | 373.47K | 501.8K | 850.13K | 860.1K | 844.42K | 778.71K | 435.55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.88M | 2.56M | 1.96M | 1.76M | 2.91M | 1.55M | 1.66M | 1.66M | 183.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 42.54M | 47.05M | 29.78M | 29.97M | 28.38M | 45.05M | 48.01M | 30.34M | 24.01M | 13.7M | 4.87M | 1.91M | 1.76M | 920.73K | 1.4K | 20K | 17.95K | 4.6K |
| Total Debt | 18.48M | 19.97M | 11.82M | 12.42M | 12.03M | 27.12M | 32.04M | 19.29M | 16.58M | 10.18M | 3.2M | 474.14K | 504.12K | 165K | 0 | 0 | 15.87K | 0 |
| Net Debt | 17.97M | 19.25M | 11.51M | 8.59M | -8.72M | 26.84M | 31.41M | 19.25M | 15.71M | 9.4M | 2.48M | 276.09K | 57.51K | -699.49K | 0 | -15.24K | 15.4K | 0 |
| Debt / Equity | 0.93x | 1.08x | 0.48x | 0.34x | 0.30x | 6.19x | - | - | - | - | - | - | 0.09x | - | - | - | - | - |
| Debt / EBITDA | -1.12x | - | - | - | - | - | 10.30x | 138.93x | - | - | - | - | 0.07x | 0.57x | - | - | - | - |
| Net Debt / EBITDA | -1.09x | - | - | - | - | - | 10.10x | 138.65x | - | - | - | - | 0.01x | -2.42x | - | - | - | - |
| Interest Coverage | -6.00x | -6.30x | -14.99x | -20.40x | -2.29x | -1.19x | 1.43x | -0.80x | -0.33x | -2.79x | -1.91x | -73.00x | 95.73x | 118.37x | -6.03x | -201.68x | -3978.23x | - |
| Total Equity | 19.83M | 18.42M | 24.53M | 36.04M | 39.66M | 4.38M | -4.16M | -6.46M | -3.32M | -3.03M | -1.75M | -1.25M | 5.47M | -53.68K | -1.4K | -4.76K | -17.48K | -4.6K |
| Equity Growth % | -100.69% | -24.9% | -31.93% | -9.11% | 805.52% | 205.25% | 35.6% | -94.75% | -9.56% | -72.74% | -40.47% | -122.8% | 10296% | -3726.37% | 70.54% | 72.76% | -280.02% | - |
| Book Value per Share | 0.42 | 0.61 | 1.28 | 3.01 | 20.57 | 6.67 | -7.82 | -12.17 | -6.23 | -5.92 | -3.49 | -2.48 | 10.88 | -0.13 | -0.01 | -0.05 | -0.21 | -0.06 |
| Total Shareholders' Equity | 19.83M | 18.42M | 24.53M | 36.04M | 39.66M | 4.38M | -4.16M | -6.46M | -3.32M | -3.03M | -1.75M | -1.25M | 5.47M | -53.68K | -1.4K | -4.76K | -17.48K | -4.6K |
| Common Stock | 49.87K | 41.15K | 23.69K | 15.98K | 10.61K | 702 | 13.48K | 13.22K | 13.88K | 12.82K | 125.87K | 125.63K | 125.59K | 125.59K | 100K | 24.51K | 24.22K | 20K |
| Retained Earnings | -135.97M | -133.17M | -114.02M | -91.64M | -66.23M | -34.35M | -18.75M | -19.57M | -16.27M | -7.21M | -1M | -401.22K | 6.29M | 242K | -4.59K | 0 | -3.79M | 0 |
| Treasury Stock | -917.16K | -917.16K | -917.16K | -917.16K | -816.71K | -816.71K | -611.85K | -411.85K | -225.49K | -95.88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 36.44K | 331.5K | -2.13M | -419.84K | -1.13M | -151.62K | 854.9K | -16.34K | 32.83K | -1.39M | -1.05M | -1.11M | -680.97K | 11.32K | -1.25K | -3.96M | -3.79M | -4.6K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
As reported in recent financial filings, COSM's equity base has contracted from $36.0M in 2023Q4 to $18.4M by 2025Q4, reflecting a persistent erosion of shareholder value driven by recurring net losses and an inability to achieve operational scale despite aggressive top-line expansion efforts.
The consistent decline in equity suggests that the company's growth strategy is currently value-destructive, as the capital raised or retained is being consumed by operating deficits rather than asset appreciation. Investors should monitor whether this trajectory forces a pivot toward more conservative capital allocation or if the current trend of balance sheet depletion continues unabated.
Based on the company's reported figures, the debt-to-equity ratio has climbed from 0.34 in 2023Q4 to 1.08 in 2025Q4, indicating that management is increasingly relying on debt financing to bridge the gap between operational cash outflows and the capital requirements of its distribution business.
This shift toward higher leverage is particularly concerning given the company's negative operating margins, as it increases the interest burden on a business that lacks a reliable cash-generative core. The reliance on debt in a high-rate environment may indicate a lack of alternative financing options, potentially limiting future strategic flexibility.
According to the most recent balance sheet data, COSM's cash reserves have plummeted to just $715.7K as of 2025Q4, a level that appears dangerously insufficient to support the company's $65.3M TTM revenue scale and ongoing working capital requirements in the volatile pharmaceutical distribution sector.
The current ratio hovering near 1.00 suggests that the company has virtually no margin for error regarding its short-term obligations. This liquidity profile warrants significant caution, as any delay in accounts receivable collection or a sudden spike in supplier payment demands could trigger a severe solvency event.
As evidenced by the quarterly balance sheets, retained earnings have deepened to a deficit of $133.2M in 2025Q4, signaling that years of operational losses have systematically depleted the company's equity and necessitated a reliance on external capital to maintain basic business continuity.
The persistent negative retained earnings highlight a fundamental disconnect between the company's revenue growth and its ability to generate internal capital. This trend suggests that shareholders may face continued dilution as the company likely seeks to replenish its equity base to offset the ongoing cash burn.
Based on the reported figures, the company's reliance on $11.8M in net PPE and the potential volatility of its intangible assets suggest that the balance sheet may be overstating the tangible value available to creditors in the event of a liquidation or operational restructuring.
The concentration of assets in PPE and potentially illiquid inventory creates a risk where the book value of assets may not reflect their actual market value during a distress scenario. Investors should be wary of the quality of these assets, as they appear to be failing to generate the returns necessary to justify their carrying values.
Quick answers to the most common questions about buying COSM stock.
As of 2025, Cosmos Health Inc. (COSM) had total assets of $65.5M including $38.4M in current assets.
Cosmos Health Inc. (COSM) carries total debt of $20.0M, offset by $0.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Cosmos Health Inc. (COSM) has total shareholders' equity (book value) of $18.4M ($0.61 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Cosmos Health Inc. (COSM) reported a current ratio of 1.00x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.